SCHEMBL10299209

SCHEMBL10299209

COc1ccc(N=CC=O)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
CYP1B1 Q16678 1/20 0.41
ERN1 O75460 1/20 0.39
TRIM24 O15164 1/20 0.39
TYR P14679 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
CYP2A6 P11509 1/20 0.37
HTT P42858 2/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 1/20 0.36
RORC P51449 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADRA2A P08913 1/20 0.35
TUBB1 Q9H4B7 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
PKM P14618 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13322457 0.78 RORC (0.42) ALDH1A1HPGDHSD17B10HTTKDM4E
SCHEMBL7093426 0.78 CYP3A4 (0.56) ALDH1A1HPGDHSD17B10HTTKDM4E
SCHEMBL13590029 0.77 ALDH1A1 (0.38) ALDH1A1HPGDHSD17B10HTTKDM4E
SCHEMBL11287730 0.76 CYP3A4 (0.64) ALDH1A1HPGDHSD17B10CYP1B1CYP2A6
SCHEMBL11287732 0.76 CYP3A4 (0.64) ALDH1A1HPGDHSD17B10CYP1B1CYP2A6
SCHEMBL8421873 0.76 SMN1; SMN2 (0.42) ALDH1A1HPGDHSD17B10CYP1B1CYP2A6
SCHEMBL13590028 0.74 ESR1 (0.41) ALDH1A1HTTKDM4ELMNACYP3A4
SCHEMBL4133933 0.74 KDM4E (0.42) ALDH1A1HPGDHSD17B10CYP1B1CYP2A6
SCHEMBL13556406 0.72 KMT2A (0.38) ALDH1A1CYP1B1HTTKDM4EGAA
SCHEMBL14459430 0.72 S100B (0.49) ALDH1A1CYP2A6GAAPKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466200-B2 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors MERCK PATENT GMBH (DE) 2013-06-18 US disclosed
US-20120172396-A1 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-07-05 US disclosed
US-20070161619-A1 Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof ASTRAZENECA AB (SE) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172396-A1 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS HSD11B1, HSD11B2, HSD17B1 ALDH1A1 90/4885HPGD 54/4885HSD17B10 15/4885
US-20070161619-A1 Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof OPRL1, OPRD1, OPRK1 ALDH1A1 1036/4885HPGD 410/4885HSD17B10 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.